Karina Silina

Karina Silina

Auto-generated profile, based on publicly available information

Karina Silina

Institute of Pharmaceutical Sciences, ETH Zurich 1 , Zurich

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Cell
Verified
Journal Article
Open access
JWJohanna Wagner
Johanna Wagner
MRMaria Anna Rapsomaniki
Maria Anna Rapsomaniki
SCStéphane Chevrier
Stéphane Chevrier
TATobias Anzeneder
Tobias Anzeneder
CLClaus Langwieder
Claus Langwieder
BBBernd Bodenmiller
Bernd Bodenmiller
Breast cancer is a heterogeneous disease. Tumor cells and associated healthy cells form ecosystems that determine disease progression and response to therapy. To characterize features of breast cancer ecosystems and their associations with clinical data, we analyzed 144 human breast tumor and 50 non-tumor tissue samples using mass cytometry. The expression of 73 proteins in 26 million cells was evaluated using tumor and immune cell-centric antibody panels. Tumors displayed individuality in tumor cell composition, including phenotypic abnormalities and phenotype dominance. Relationship analyses between tumor and immune cells revealed characteristics of ecosystems related to immunosuppression and poor prognosis. High frequencies of PD-L1+ tumor-associated macrophages and exhausted T cells were found in high-grade ER+ and ER- tumors. This large-scale, single-cell atlas deepens our understanding of breast tumor ecosystems and suggests that ecosystem-based patient classification will facilitate identification of individuals for precision medicine approaches targeting the tumor and its immunoenvironment.

12 October 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NDNick van Dijk
Nick van Dijk
AGAlberto Gil-Jimenez
Alberto Gil-Jimenez
KSKarina Silina
Karina Silina
KHKees Hendricksen
Kees Hendricksen
LSLaura A. Smit
Laura A. Smit
MHMichiel S. van der Heijden
Michiel S. van der Heijden

18 December 2017 in OncoImmunology
Verified
Journal Article
Open access
FPFlorian Posch
Florian Posch
KSKarina Silina
Karina Silina
SLSebastian Leibl
Sebastian Leibl
AMAxel Mündlein
Axel Mündlein
HMHolger Moch
Holger Moch
TWThomas Winder
Thomas Winder
Tertiary lymphoid structures (TLS) are associated with favorable outcome in non-metastatic colorectal carcinoma (nmCRC), but the dynamics of TLS maturation and its association with effective anti-tumor immune surveillance in nmCRC are unclear. Here, we hypothesized that not only the number of TLS but also their composition harbors information on recurrence risk in nmCRC. In a comprehensive molecular, tissue, laboratory, and clinical analysis of 109 patients with stage II/III nmCRC, we assessed TLS numbers and degree of maturation in surgical specimens by multi-parameter immunofluorescence of follicular dendritic cell (FDC) and germinal center (GC) markers. TLS formed in most tumors and were significantly more prevalent in highly-microsatellite-instable (MSI-H) and/or BRAF-mutant nmCRC. We could distinguish three sequential TLS maturation stages which were characterized by increasing prevalence of FDCs and mature B-cells: [1] Early TLS, composed of dense lymphocytic aggregates without FDCs, [2] Primary follicle-like TLS, having FDCs but no GC reaction, and [3] Secondary follicle-like TLS, having an active GC reaction. A simple integrated TLS immunoscore reflecting these parameters identified a large subgroup of nmCRC patients with a very low risk of recurrence independently of clinical co-variables such as ECOG performance status, age, stage, and adjuvant chemotherapy. We conclude that (1) mismatch repair and BRAF mutation status are associated with the formation of TLS in nmCRC, (2) TLS formation in nmCRC follows sequential maturation steps, culminating in germinal center formation, and (3) this maturation process harbors important prognostic information on the risk of disease recurrence.

12 April 2023 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
YSYuki Sato
Yuki Sato
KSKarina Silina
Karina Silina
MBMaries van den Broek
Maries van den Broek
KHKiyoshi Hirahara
Kiyoshi Hirahara
MYMotoko Yanagita
Motoko Yanagita

1 February 2021 in Medical Image Analysis
Verified
Journal Article
Open access
MRMart van Rijthoven
Mart van Rijthoven
MBMaschenka Balkenhol
Maschenka Balkenhol
KSKarina Siliņa
Karina Siliņa
JLJeroen van der Laak
Jeroen van der Laak
FCFrancesco Ciompi
Francesco Ciompi
We propose HookNet, a semantic segmentation model for histopathology whole-slide images, which combines context and details via multiple branches of encoder-decoder convolutional neural networks. Concentric patches at multiple resolutions with different fields of view, feed different branches of HookNet, and intermediate representations are combined via a hooking mechanism. We describe a framework to design and train HookNet for achieving high-resolution semantic segmentation and introduce constraints to guarantee pixel-wise alignment in feature maps during hooking. We show the advantages of using HookNet in two histopathology image segmentation tasks where tissue type prediction accuracy strongly depends on contextual information, namely (1) multi-class tissue segmentation in breast cancer and, (2) segmentation of tertiary lymphoid structures and germinal centers in lung cancer. We show the superiority of HookNet when compared with single-resolution U-Net models working at different resolutions as well as with a recently published multi-resolution model for histopathology image segmentation. We have made HookNet publicly available by releasing the source code1 as well as in the form of web-based applications2,3 based on the grand-challenge.org platform.

20 November 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SGSoizic Garaud
Soizic Garaud
PZPawel Zayakin
Pawel Zayakin
LBLaurence Buisseret
Laurence Buisseret
URUndine Rulle
Undine Rulle
KSKarina Silina
Karina Silina
ALAija Linē
Aija Linē
An important role for tumor infiltrating B lymphocytes (TIL-B) in the immune response to cancer is emerging; however, very little is known about the antigen specificity of antibodies produced in situ. The presence of IgA antibodies in the tumor microenvironment has been noted although their biological functions and clinical significance are unknown. This study used a 91-antigen microarray to examine the IgG and IgA autoantibody repertoires in breast cancer (BC). Tumor and adjacent breast tissue supernatants and plasma from BC patients together with normal breast tissue supernatants and plasma from healthy controls (patients undergoing mammary reduction and healthy blood donors) were analyzed to investigate relationships between autoantibodies and the clinical, histological and immunological features of tumors. Our data show that >84% of the BC samples tested contain autoantibodies to one or more antigens on the array, with ANKRD30BL, COPS4, and CTAG1B being most frequently reactive. Ex vivo TIL-B responses were uncoupled from systemic humoral responses in the majority of cases. A comparison of autoantibody frequencies in supernatants and plasma from patients and controls identified eight antigens that elicit BC-associated autoantibody responses. The overall prevalence of IgG and IgA autoantibodies was similar and while IgG and IgA responses were not linked they did correlate with distinct clinical, pathological and immunological features. Higher levels of ex vivo IgG responses to BC-associated antigens were associated with shorter recurrence-free survival (RFS), HER2 overexpression and lower tumor-infiltrating CD8+ T cell counts. Higher IgA levels were associated with estrogen and progesterone receptor-negative cancers but were not significantly associated with RFS. Furthermore, ex vivo IgA but not IgG autoantibodies reactive to BC-associated antigens were linked with germinal center and early memory B cell maturation and the presence of tertiary lymphoid structures suggesting that these TIL-B are activated in the tumor microenvironment. Overall, our results extend the current understanding of the antigen specificity, the biological and the clinical significance of IgG and IgA autoantibodies produced by BC TIL-B in situ.